Recombinant Viral Macrophage Inflammatory Protein-2
Viral MIP-2 is one of the three chemokine-like proteins expressed by the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus, KSHV) and the other is ViMIP-1 and ViMIP-3. It shares 41 % and 48 % with human MIP-1α and ViMIP-1, respectively. ViMIP-2 has been shown to have antagonist activity towards a wide range of chemokine receptors and has functions of blocking infection by several different human immunodeficiency virus type 1 (HIV-1) strains. It may form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-I interactions. Additionally, ViMIP-2 has been shown to activate and chemoattract human eosinphils.
Reference
1. Liwang AC, Wang ZX, Sun Y, et al. 1999. Protein Sci, 8: 2270-80
2. Morris KV, Higgins J, Shen X, et al. 2003. Virus Res, 94: 103-12
3. Luttichau HR. 2008. Virol J, 5: 50
4. Shao W, Fernandez E, Sachpatzidis A, et al. 2001. Eur J Biochem, 268: 2948-59.
| Gene ID | 4961514 |
| Accession # | Q98157 |
| Alternate Names | Viral Macrophage Inflammatory Protein II, vMIP-1B, MIP-II, vMIP-2 |
| Source | Escherichia coli. |
| M.Wt | Approximately 8.0 kDa, a single, non-glycosylated polypeptide chain containing 70 amino acids. |
| AA Sequence | LGASWHRPDK CCLGYQKRPL PQVLLSSWYP TSQLCSKPGV IFLTKRGRQV CADKSKDWVK KLMQQLPVTA |
| Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 150mM NaCl. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Biological Activity | Fully biologically active when compared to standard. The specific activity is determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0μg-10.0μg/ml of viral MIP-2 will inhibit 25ng/ml of human MIP-1 alpha. |
| Shipping Condition | Gel pack. |
| Handling | Centrifuge the vial prior to opening. |
| Usage | For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 97 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/μg of rViMIP-2 as determined by LAL method.